Aardvark Therapeutics, Inc. (AARD) vs AbbVie Inc. (ABBV)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| AARD | ABBV | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
| Size band | NANO | MEGA |
| Listing | Nasdaq GS | NYSE |
| Country | United States | United States |
| Theme | rare-disease | pharmaceuticals-large-cap |
| Price and returns | ||
| Last close | $1.08 | $286.74 |
| Return · 1 week | −71.12% | +1.44% |
| Return · 1 month | −79.51% | +7.68% |
| Return · 3 months | −83.18% | +8.94% |
| Return · year to date | −91.81% | +27.10% |
| Return · 1 year | −90.76% | +27.81% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −93.49% | −1.60% |
| 52-week high | $16.60 | $291.40 |
| 52-week low | $0.93 | $190.75 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $23.64M | $506.70B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $128.14K | $1.26B |
| Employees | 28 | 57,000 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | 78.10× |
| Price to earnings · forward | n/a (negative forward earnings) | 17.00× |
| Price to sales | — | 7.59× |
| Price to book | 0.41× | n/a (negative book value) |
| Enterprise value to EBITDA | 0.58× | 17.68× |
| Enterprise value to revenue | — | 8.45× |
| PEG ratio | — | 0.55 |
| Earnings per share · trailing | -3.21 | 3.54 |
| Profitability | ||
| Gross margin | — | 71.48% |
| Operating margin | 0.00% | 40.04% |
| Profit margin | — | 9.74% |
| Return on equity | −66.02% | — |
| Return on assets | −40.38% | 10.51% |
| Growth | ||
| Revenue growth | — | +10.20% |
| Earnings growth | — | +290.40% |
| Balance sheet and payout | ||
| Debt / equity (%) | 0.91 | — |
| Current ratio | 12.63 | 0.81 |
| Dividend yield | 0.00% | 2.55% |
| Payout ratio | — | 190.40% |
| Trend and volatility | ||
| RSI · 14 | 19.17 | 66.15 |
| ADX · 14 | 31.19 | 34.31 |
| 50-day average | $5.17 | $266.87 |
| 200-day average | $6.59 | $235.72 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 56.51% | 2.44% |
The full AARD analysis
Everything this table leaves out for Aardvark Therapeutics, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the AARD argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full AARD analysisThe full ABBV analysis
Everything this table leaves out for AbbVie Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the ABBV argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full ABBV analysis